TWD
NMRA icon

True Wealth Design’s Neumora Therapeutics NMRA Stock Holding History

True Wealth Design’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$49 Buy
+81
New +$112 ﹤0.01% 2510
2025
Q4 		– Sell
-815
Closed -$1.48K – 2739
2025
Q3 		$1.48K Sell
815
-730
-47% -$1.18K ﹤0.01% 1598
2025
Q2 		$1.13K Buy
1,545
+1,474
+2,076% +$1.12K ﹤0.01% 1417
2025
Q1 		$71 Buy
+71
New +$122 ﹤0.01% 2303

Other funds holding NMRA

LPT
Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

True Wealth Design's NMRA Position: Q3 2026 in Review

True Wealth Design opened a new position in Neumora Therapeutics (NMRA) in Q3 2026: 81 shares worth $49. The stake represents ﹤0.01% of the portfolio and ranks #2510 among its holdings. This is a return to the name: True Wealth Design previously reported a position in NMRA as recently as Q3 2025.

True Wealth Design first reported a position in NMRA in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.48K in Q3 2025. 6 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

  • True Wealth Design held 81 shares of Neumora Therapeutics worth $49 as of Q3 2026.
  • Neumora Therapeutics was a new True Wealth Design position in Q3 2026.
  • Neumora Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2510 holding.
  • True Wealth Design first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • True Wealth Design's Neumora Therapeutics position peaked at $1.48K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.